Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $75.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (ESALF) Snapshot

Open
$75.00
Previous Close
$75.00
Day High
$75.00
Day Low
$75.00
52 Week High
03/24/15 - $80.10
52 Week Low
12/1/14 - $35.85
Market Cap
22.2B
Average Volume 10 Days
18.6K
EPS TTM
--
Shares Outstanding
296.6M
EX-Date
03/27/15
P/E TM
--
Dividend
$156.29
Dividend Yield
1.75%
Current Stock Chart for EISAI CO LTD (ESALF)

Related News

No related news articles were found.

eisai co ltd (ESALF) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (ESALF) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (ESALF) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥115.0M
Chief Clinical Officer of Eisai Product Creat...
Total Annual Compensation: ¥84.0M
Compensation as of Fiscal Year 2014.

eisai co ltd (ESALF) Key Developments

Eisai Co., Ltd. and Epizyme, Inc. to Change the Scope of Collaboration for Their Partnership Initiated in March 2011 to Discover, Develop and Commercialize Cancer Therapeutics Targeting EZH2, an Epigenetic Enzyme

Eisai Co., Ltd. and Epizyme, Inc. have agreed to change the scope of collaboration for their partnership initiated in March 2011 to discover, develop and commercialize cancer therapeutics targeting EZH2, an epigenetic enzyme. In March 2011, Eisai and Epizyme entered into a collaboration agreement concerning the discovery, development and commercialization of cancer therapeutics targeting the epigenetic enzyme EZH2 for the treatment of non-Hodgkin B-cell lymphoma and other cancers. Under this agreement, Eisai has been conducting a phase I/II clinical study of the EZH2 inhibitor E7438 (Epizyme development code: EPZ-6438) in patients with advanced solid tumors or non-Hodgkin B-cell lymphoma. Eisai and Epizyme have revised the scope of their partnership for worldwide development and commercialization rights for anticancer therapies targeting EZH2, including E7438, with Epizyme assuming responsibility for development and commercialization in regions outside of Japan and Eisai retaining responsibility for development and commercialization within Japan as well as having the right of first negotiation for licensing rights in Asia. The decision to change the scope of the partnership was agreed upon by the two companies in consideration of the priorities of each company's pipeline strategy and the maximization of the potential value of the compounds including E7438. Based on this change in the agreement, Eisai will receive from Epizyme a contractual one-time payment as well as milestone payments as projects progress and marketing authorization is obtained. The companies will pay royalties to one another dependent upon on the sales in each company's respective sales regions after launch. Eisai considers oncology a therapeutic area of focus and is committed to the development of new anticancer agents and treatments for supportive care. Eisai strives to further contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer and their families.

Epizyme, Inc. Enters into an Amended and Restated Collaboration and License Agreement with Eisai Co. Ltd

On March 11, 2015, the Epizyme Inc. entered into an amended and restated collaboration and license agreement with Eisai Co. Ltd., or Eisai, under which the company reacquired worldwide rights, excluding Japan, to its EZH2 program, including EPZ-6438. Under the amended and restated collaboration agreement, the company will be responsible for global development, manufacturing and commercialization outside of Japan of EPZ-6438 and any other EZH2 product candidates, with Eisai retaining development and commercialization rights in Japan, as well as a right to elect to manufacture EPZ-6438 and any other EZH2 product candidates in Japan. Under the original collaboration and license agreement, the company had granted Eisai an exclusive worldwide license to its small molecule HMT inhibitors directed to EZH2, including EPZ-6438, while retaining an opt-in right to co-develop, co-commercialize and share profits with Eisai as to licensed products in the United States. Upon the execution of the amended and restated collaboration and license agreement, the company agreed to pay Eisai a $40.0 million upfront payment. The company also agreed to pay Eisai up to $20.0 million in clinical development milestone payments, up to $50.0 million in regulatory milestone payments and royalties at a percentage in the mid-teens on worldwide net sales of any EZH2 product, excluding net sales in Japan. The company is eligible to receive from Eisai royalties at a percentage in the mid-teens on net sales of any EZH2 product in Japan. Under the original agreement, Eisai was solely responsible for funding all research, development and commercialization costs for licensed compounds. Under the amended agreement, the company will be solely responsible for funding global development and commercialization costs for EZH2 compounds outside of Japan, and Eisai will be solely responsible for funding Japan-specific development and commercialization costs for EZH2 compounds. In connection with the amendment and restatement of the collaboration and license agreement with Eisai, the company and Eisai have agreed upon a transition to the company of ongoing development and manufacturing activities being conducted by or on behalf of Eisai. In the event that the company seeks to license rights to a third party to develop or commercialize an EZH2 product in any country in Asia other than Japan, Eisai has a limited right of first negotiation for such rights. In the event that the company is awarded a priority review voucher from the FDA with respect to an EZH2 product, Eisai is entitled to specified compensation if the company uses the voucher on a non-EZH2 program or sells the voucher to a third party.

Eisai and Merck's Subsidiary Enter into Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy Multi-Targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer

Eisai Co., Ltd. and Merck, through a subsidiary, announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. under the brand name LENVIMA, 'lenvatinib') and eribulin mesylate (a microtubule dynamics inhibitor marketed in nearly 60 countries including Japan, the U.S., and Europe under the brand name HALAVEN, 'eribulin') in multiple clinical trials. The planned studies include a multicenter, open-label Phase 1b/2 study of lenvatinib plus pembrolizumab in select solid tumors and an open-label, single-arm, multicenter Phase 1b/2 study to evaluate the efficacy and safety of eribulin in combination with pembrolizumab in metastatic triple-negative breast cancer. Eisai and Merck will establish a Joint Development Committee to oversee clinical development activities. The studies are expected to begin in the second half of 2015. Financial terms of the agreement were not disclosed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESALF:US $75.00 USD 0.00

ESALF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €16.92 EUR +0.36
Ono Pharmaceutical Co Ltd ¥13,400 JPY -360.00
Salix Pharmaceuticals Ltd $172.60 USD -0.03
Santen Pharmaceutical Co Ltd ¥1,755 JPY +11.00
Shire PLC 5,425 GBp +115.00
View Industry Companies
 

Industry Analysis

ESALF

Industry Average

Valuation ESALF Industry Range
Price/Earnings 62.9x
Price/Sales 4.5x
Price/Book 4.3x
Price/Cash Flow 65.3x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.